TR200101082T2 - Bilinci veya algılama yeteneğini geliştirici bileşimler. - Google Patents

Bilinci veya algılama yeteneğini geliştirici bileşimler.

Info

Publication number
TR200101082T2
TR200101082T2 TR2001/01082T TR200101082T TR200101082T2 TR 200101082 T2 TR200101082 T2 TR 200101082T2 TR 2001/01082 T TR2001/01082 T TR 2001/01082T TR 200101082 T TR200101082 T TR 200101082T TR 200101082 T2 TR200101082 T2 TR 200101082T2
Authority
TR
Turkey
Prior art keywords
active ingredient
perception
alzheimer
disease
compositions
Prior art date
Application number
TR2001/01082T
Other languages
English (en)
Turkish (tr)
Inventor
Leonce Irma De Nijs Paul
Louis Julien Parys Wim
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of TR200101082T2 publication Critical patent/TR200101082T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TR2001/01082T 1998-10-16 1999-10-12 Bilinci veya algılama yeteneğini geliştirici bileşimler. TR200101082T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16

Publications (1)

Publication Number Publication Date
TR200101082T2 true TR200101082T2 (tr) 2001-09-21

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01082T TR200101082T2 (tr) 1998-10-16 1999-10-12 Bilinci veya algılama yeteneğini geliştirici bileşimler.

Country Status (20)

Country Link
EP (1) EP1121131A2 (xx)
JP (1) JP2002527469A (xx)
KR (1) KR20010072878A (xx)
CN (1) CN1367697A (xx)
AU (1) AU6472799A (xx)
BG (1) BG105302A (xx)
BR (1) BR9914419A (xx)
CA (1) CA2345767A1 (xx)
EE (1) EE200100136A (xx)
HK (1) HK1039745A1 (xx)
HR (1) HRP20010262A2 (xx)
HU (1) HUP0103781A3 (xx)
ID (1) ID28441A (xx)
IL (1) IL142588A0 (xx)
NO (1) NO20011403D0 (xx)
PL (1) PL348107A1 (xx)
SK (1) SK4592001A3 (xx)
TR (1) TR200101082T2 (xx)
WO (1) WO2000023057A2 (xx)
ZA (1) ZA200103081B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
EP1441727B1 (en) 2001-10-30 2010-12-29 Novartis AG Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
JP2008523058A (ja) * 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK1011678T3 (da) * 1997-08-11 2008-05-05 Univ South Florida Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
ATE369848T1 (de) * 1998-04-14 2007-09-15 Gen Hospital Corp Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie

Also Published As

Publication number Publication date
NO20011403L (no) 2001-03-20
WO2000023057A3 (en) 2000-07-27
HRP20010262A2 (en) 2002-06-30
NO20011403D0 (no) 2001-03-20
CN1367697A (zh) 2002-09-04
IL142588A0 (en) 2002-03-10
EP1121131A2 (en) 2001-08-08
WO2000023057A2 (en) 2000-04-27
SK4592001A3 (en) 2001-12-03
PL348107A1 (en) 2002-05-06
KR20010072878A (ko) 2001-07-31
HK1039745A1 (zh) 2002-05-10
ZA200103081B (en) 2002-07-12
ID28441A (id) 2001-05-24
EE200100136A (et) 2002-06-17
BG105302A (en) 2001-11-30
CA2345767A1 (en) 2000-04-27
AU6472799A (en) 2000-05-08
HUP0103781A3 (en) 2003-09-29
HUP0103781A2 (hu) 2002-03-28
BR9914419A (pt) 2001-06-26
JP2002527469A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
TR200101082T2 (tr) Bilinci veya algılama yeteneğini geliştirici bileşimler.
DE59106756D1 (de) Neuartige Antiepileptika.
HUP0102521A2 (hu) Sztilbénszármazékot és platina koordinációs vegyületet tartalmazó daganatellenes szer
DE60205234D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
TR200100172T2 (tr) Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
ES2153975T3 (es) Derivados de pirimidona con actividad antifungica.
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
MX9701946A (es) Solucion oftalmica transportadora.
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
TR199700878T1 (xx) Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
DE59609926D1 (de) Stabilisierte schilddrüsenhormonhaltige arzneimittel
TR200003736T2 (tr) Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi
TR200200449T2 (tr) Klonidin içeren etken madde kombinasyonu
EA199900876A1 (ru) Фармацевтические композиции против кашля
HUP0303935A2 (hu) Ketolid baktériumellenes vegyületek
SE8103369L (sv) Antiperspirantkomposition innehallande en aluminiumklorid och en aluminiumzirkoniumhydroxiklorid som aktiva bestandsdelar och sett att inhibera perspiration
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
MXPA03000606A (es) Derivados de benzofurano y su uso como agentes antibacterianos.
YU25001A (sh) Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
DK0917460T3 (da) Cyclosporin-formulering
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung